BRIEF published on 11/05/2026 at 14:53, 1 day 18 hours ago Formycon Adjusts 2026 Financial Outlook Amid Market Changes Adjusted EBITDA Formycon Market Competition 2026 Guidance FYB201 & FYB202
BRIEF published on 11/05/2026 at 14:49, 1 day 18 hours ago Formycon AG Reports Non-Cash Impairments and Revises EBITDA Guidance EBITDA Guidance Formycon AG Financial Outlook Non-cash Impairments FYB201 And FYB202
PRESS RELEASE published on 11/05/2026 at 14:48, 1 day 18 hours ago Formycon maintains 2026 guidance for revenue, EBITDA and working capital, revises adjusted EBITDA and reassesses FYB201 and FYB202
PRESS RELEASE published on 11/05/2026 at 14:44, 1 day 18 hours ago EQS-Adhoc: Formycon AG recognizes non-cash impairments on FYB201 and FYB202 and revises its guidance for adjusted EBITDA
BRIEF published on 11/05/2026 at 06:35, 2 days 2 hours ago Formycon AG Hosts Conference Call and Attends Investor Conferences Investor Conferences Formycon AG Biosimilars Financial Outlook Nine-month Results
PRESS RELEASE published on 11/05/2026 at 06:30, 2 days 2 hours ago Formycon invites to conference call on 2026 nine-month results and announces participation in international investor conferences
BRIEF published on 11/03/2026 at 14:52, 3 days 18 hours ago Formycon AG's Keytruda Biosimilar Gains FDA Acceptance Formycon AG Market Entry FYB206 Keytruda Biosimilar FDA Acceptance
PRESS RELEASE published on 11/03/2026 at 14:47, 3 days 18 hours ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
BRIEF published on 10/21/2026 at 06:35, 17 days 2 hours ago Formycon and Biocelys Initiate FYB286 Biosimilar Project Strategic Partnership Emerging Markets Pharmaceutical Manufacturing Biosimilar Development FYB286
PRESS RELEASE published on 10/21/2026 at 06:30, 17 days 2 hours ago Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286 Formycon and Biocelys partner on biosimilar project FYB286, combining expertise for cost-effective development. Santo Biosimilar GmbH funds collaboration Biosimilar Formycon FYB286 Biocelys Santo Biosimilar GmbH
Published on 11/06/2026 at 22:15, 11 hours 6 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 20 hours 21 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 20 hours 51 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 20 hours 51 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 20:15, 13 hours 6 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 14 hours 6 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 14 hours 21 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 14 hours 49 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 18:00, 15 hours 21 minutes ago ARVERNE GROUP: Number shares and voting rights
Published on 11/06/2026 at 18:00, 15 hours 21 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 11/06/2026 at 17:54, 15 hours 27 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 15 hours 46 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
